Process research and development of an NK-1 receptor antagonist. enantioselective trifluoromethyl addition to a ketone in the preparation of a chiral isochroman

被引:75
作者
Caron, Stephane [1 ]
Do, Nga M. [1 ]
Sieser, Janice E. [1 ]
Arpin, Patrice [1 ]
Vazquez, Enrique [1 ]
机构
[1] Pfizer Global R&D, Chem R&D, Groton, CT 06340 USA
关键词
D O I
10.1021/op7001886
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
CJ-17,493 (4) is a chiral NK-1 receptor antagonist. It was first prepared through a diastereoselective crystallization, then through chiral chromatography of a key intermediate, and ultimately via asymmetric synthesis. Multiple routes for the preparation of a key isochroman were demonstrated, and conditions for improved regioselectivity of a Friedel-Crafts acylation were identified. Cesium fluoride was found to be an acceptable initiator for the generation of a nucleophilic trifluoromethyl anion from CF3TMS. A cinchonine-derived catalyst was identified for the enantioselective addition of the trifluoromethyl group to the ketone, and it was found that the product of the addition would be converted directly to the isochroman by treatment with t-BuOK. A Duff reaction was used for the formylation, and the resulting aldehyde was coupled to amine 5 to afford CJ-17,493 (4).
引用
收藏
页码:1015 / 1024
页数:10
相关论文
共 30 条
  • [1] A review on the use of sodium triacetoxyborohydride in the reductive amination of ketones and aldehydes
    Abdel-Magid, Ahmed F.
    Mehrman, Steven J.
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2006, 10 (05) : 971 - 1031
  • [2] 1,2-DI(LITHIOMETHYL)BENZENE FROM PHTHALAN - SEQUENTIAL INTRODUCTION OF 2 DIFFERENT ELECTROPHILES
    ALMENA, J
    FOUBELO, F
    YUS, M
    [J]. TETRAHEDRON, 1995, 51 (11) : 3351 - 3364
  • [3] Phenanthrene syntheses with 2,3-dimethyl-2cyclohexen-1-one
    Bergmann, E
    Weizmann, A
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1939, 4 (03) : 266 - 269
  • [4] Caron S, 2003, SYNTHESIS-STUTTGART, P1693
  • [5] An efficient and cost-effective synthesis of 2-phenyl-3-aminopyridine
    Caron, S
    Massett, SS
    Bogle, DE
    Castaldi, MJ
    Braish, TF
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2001, 5 (03) : 254 - 256
  • [6] Tachykinins and neuropsychiatric disorders
    Chahl, Loris A.
    [J]. CURRENT DRUG TARGETS, 2006, 7 (08) : 993 - 1003
  • [7] Collet A, 1998, ANGEW CHEM INT EDIT, V37, P3239, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3239::AID-ANIE3239>3.0.CO
  • [8] 2-U
  • [9] Recovery of carbonyl compounds from N,N-dialkylhydrazones
    Enders, D
    Wortmann, L
    Peters, R
    [J]. ACCOUNTS OF CHEMICAL RESEARCH, 2000, 33 (03) : 157 - 169
  • [10] Structural optimization affording 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist
    Hale, JJ
    Mills, SG
    MacCoss, M
    Finke, PE
    Cascieri, MA
    Sadowski, S
    Ber, E
    Chicchi, GG
    Kurtz, M
    Metzger, J
    Eiermann, G
    Tsou, NN
    Tattersall, FD
    Rupniak, NMJ
    Williams, AR
    Rycroft, W
    Hargreaves, R
    MacIntyre, DE
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (23) : 4607 - 4614